More Is Better, Right? Panel vs. Targeted Testing

There has been rapid evolution in genetic testing from simple single gene markers to now a whole “omic” approach fueled largely by rapid technological advancements, followed by the completion of Human Genome Project. This talk will explore some of the advances in genetic/genomic testing and efforts to evaluate evidence and to standardize testing as well as exploring the future of genomic testing.

Lecture Presenter
Image
Victoria M. Pratt, PhD, FACMG
Victoria M. Pratt, PhD, FACMG
Vice President, Molecular Diagnostics Quality Assessments, Optum Genomics

Dr. Pratt is a medical and clinical molecular geneticist board-certified by the American College of Medical Genetics. Prior to joining Optum Genomics, she was the Laboratory Director of Pharmacogenomics and Molecular Genetics at the Indiana University School of Medicine. She continues to be adjunct professor of medical and molecular genetics at Indiana University.

Dr. Pratt is the past president of the association for Molecular Pathology. Dr. Pratt continues to serve on the CDC Genetic Testing Reference Materials (GeT-RM) Coordination Program, which coordinates reference materials for molecular genetics; the National Academy of Medicine’s Roundtable on Genomics and Precision Health; and the American Medical Association’s (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory Committee.

Dr. Pratt graduated with a PhD in medical and molecular genetics from Indiana University School of Medicine. Her fellowship training was in PhD medical and clinical molecular genetics at Henry Ford Hospital, Detroit.

Objectives

After this presentation, participants will be able to:

Understand the evolution of genomic testing
Differentiate evidence of genes included in genomic panel testing
Describe standardization efforts for pharmacogenomic tests